Hypertension News

The FDA approved a second renal denervation device to treat adults with uncontrolled hypertension despite an advisory panel’s vote regarding that system’s risks and benefits, Medtronic announced.

PHILADELPHIA — The rate of hypertension among patients with chronic kidney disease has increased. Yet even with more medication being prescribed, most patients are not reaching blood pressure goals, researchers said at ASN Kidney Week.

PHILADELPHIA — Zilebesiran, an investigational subcutaneous RNA interference therapeutic, lowered systolic blood pressure at 3 months and sustained the reduction to 6 months, according to results of the phase 2 KARDIA-1 trial.

The FDA approved the first renal denervation device to treat adults with hypertension not adequately controlled with lifestyle changes and medications, ReCor Medical announced.

PHILADELPHIA — Obesity-associated dysregulated aldosterone is an endotype predictive of response to lorundrostat for patients with uncontrolled or treatment-resistant hypertension, according to data presented at ASN Kidney Week.

SAN FRANCISCO — A new pooled analysis showed a maintained BP-lowering effect with fewer added medications after treatment with an ultrasound renal denervation system compared with a sham procedure, a speaker reported at TCT 2023.

Remote BP monitoring and use of a bilingual phone app improved BP control among more than half of participants with initially uncontrolled hypertension, a speaker reported.

An investigational RNA interference agent targeting angiotensin demonstrated a dose-dependent, clinically significant reduction in 24-hour mean systolic BP in adults with hypertension in a phase 2 trial, according to a press release.

A slim majority of FDA advisory panelists rejected that the benefits of a radiofrequency renal denervation system outweigh the risks for use in adults with uncontrolled hypertension despite use of antihypertensive medications.

An FDA advisory panel voted 10-2 that the benefits of an ultrasound renal denervation system outweigh the risk for use in adults with uncontrolled hypertension who are unresponsive or intolerant to antihypertensive medications.